Look back at pharma news in the week to May 21, 2021

23 May 2021

By Barbara Obstoj-Cardwell. Editor

Last week, US biotech Sarepta Therapeutics impressed with early-stage data on SRP-9001, a gene therapy candidate for Duchenne muscular dystrophy under development with Roche. GlaxoSmithKline reported positive results from a Phase II trial of a plant-based COVID-19 vaccine being developed with Medicago. Ahead of the American Society of Clinical Oncology (ASCO) meeting next month, Bristol Myers Squibb last Wednesday outlined its planned presentations, with a strong focus on its next-generation checkpoint blocker relatlimab, which has implications for Immutep. Also, Eli Lilly released new data on tirzepatide compared to insulin glargine in type 2 diabetes patients.

Sarepta finds faith in big batch gene therapy data

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK